http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113072591-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113072591-B |
| titleOfInvention | Iridium complex and synthesis method and application thereof |
| abstract | The invention discloses two iridium complexes and a synthesis method and application thereof. The synthesis method of the iridium complex comprises the following steps: putting the iridium 2-phenylpyridine dimer and the 8-hydroxyquinoline derivative in an organic solvent, and reacting under heating or non-heating conditions to obtain the corresponding target complex. The test results of the applicant show that the complex of the invention has significant biological activity (the activity is significantly higher than that of the ligand and cisplatin) on cervical cancer and ovarian cancer cells, and simultaneously, the toxicity of the complex to normal human liver cells is very low (IC) 50 > 80. mu.M); on the other hand, the complex can also perform fluorescence localization on tumor cells, and can be developed into a targeted anti-cancer drug which targets mitochondria through fluorescence localization. |
| priorityDate | 2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.